Table 3.
Baseline characteristics of the 101 hypertensive patients with or without arterial stiffness
| Characteristic | Low arterial stiffness group (%) | High arterial stiffness group (%) | P value |
|---|---|---|---|
| Gender | |||
| Male | 19 (65.5) | 48 (66.7) | 0.912 |
| Female | 10 (34.5) | 24 (33.3) | |
| Diabetes | |||
| No | 21 (72.4) | 36 (50.0) | <0.001* |
| Yes | 8 (27.6) | 36 (50.0) | |
| Metabolic syndrome | |||
| No | 22 (75.9) | 16 (22.2) | <0.001* |
| Yes | 7 (24.1) | 56 (77.8) | |
| ACE inhibitor use | |||
| No | 17 (58.6) | 47 (65.3) | 0.530 |
| Yes | 12 (41.4) | 25 (34.7) | |
| ARB use | |||
| No | 14 (48.3) | 31 (43.1) | 0.633 |
| Yes | 15 (51.7) | 41 (56.9) | |
| β-blocker use | |||
| No | 12 (41.4) | 33 (45.8) | 0.684 |
| Yes | 17 (58.6) | 39 (54.2) | |
| CCB use | |||
| No | 15 (51.7) | 42 (58.3) | 0.544 |
| Yes | 14 (48.3) | 30 (41.7) | |
| Thiazide use | |||
| No | 23 (78.3) | 57 (79.2) | 0.987 |
| Yes | 6 (20.7) | 5 (20.8) | |
| Statin | |||
| No | 12 (41.4) | 31 (43.1) | 0.877 |
| Yes | 17 (58.6) | 35 (56.9) | |
| Fibrate | |||
| No | 23 (79.3) | 64 (88.9) | 0.208 |
| Yes | 6 (20.7) | 5 (11.3) | |
Data are expressed as number of patients and analysis was performed by using the Chi square test
ARB angiotensin-receptor blocker, ACE angiotensin-converting enzyme, CCB calcium-channel blocker
* P < 0.05 was considered statistically significant